TOUJEO Drug Profile

Summary for Tradename: TOUJEO

High Confidence Patents:	6
Applicants:	1
BLAs:	1
Drug Prices:	Drug price information for TOUJEO

See drug prices for TOUJEO

Pharmacology for TOUJEO

Established Pharmacologic Class	Insulin Analog
Chemical Structure	Insulin

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for TOUJEO Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for TOUJEO Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	7,713,930	2028-12-04	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	8,637,473	2031-05-03	DrugPatentWatch analysis and company disclosures
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	8,992,492	2031-09-27	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for TOUJEO Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	10,004,686	2033-06-12	Patent claims search
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	10,016,338	2036-12-20	Patent claims search
Sanofi-aventis U.s. Llc	TOUJEO	insulin glargine	Injection	206538	10,092,513	2034-04-01	Patent claims search

International Patents for TOUJEO

Country	Patent Number	Estimated Expiration
Argentina	039688
Australia	2003238471
Brazil	0311877

Supplementary Protection Certificates for TOUJEO

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
CR 2017 00020	Denmark		PRODUCT NAME: INSULIN GLARGINE/LIXISENATID; REG. NO/DATE: EU/1/16/1157/001-004 20170113
SPC/GB00/022	United Kingdom		PRODUCT NAME: INSULIN GLARGINE (LANTUS) OPTIONALLY IN THE FORM OF ESTERS THEREOF OR PHYSIOLOGICALLY TOLERATED SALTS THEREOF.; REGISTERED: UK EU/1/00/134/001 20000609; UK EU/1/00/134/002 20000609; UK EU/1/00/134/003 20000609; UK EU/1/00/134/004 20000609; UK EU/1/00/134/005 20000609; UK EU/1/00/134/006 20000609; UK EU/1/00/134/007 20000609
2017/022	Ireland		PRODUCT NAME: A COMPOSITION COMPRISING INSULIN GLARGINE, OR A PHARMACOLOGICALLY TOLERABLE SAFT THEREOF, AND LIXISENATIDE, OR A PHARMACOLOGICALLY TOLERABLE SALT THEREOF.; REGISTRATION NO/DATE: EU/1/16/1157 20170111

Market Dynamics and Financial Trajectory for TOUJEO

Last updated: April 11, 2026

What is TOUJEO?

TOUJEO (insulin glargine), manufactured by Eli Lilly and Company, is a long-acting biologic insulin indicated for people with diabetes mellitus. It provides a basal insulin supply and is designed for once-daily injection, with a formulation that extends insulin release and maintains consistent glycemic control.

Market Position and Adoption

Competitive Landscape

• TOUJEO competes with other basal insulins, primarily:
  • Novo Nordisk’s Tresiba (insulin degludec)
  • Sanofi’s Lantus (insulin glargine U-100)
  • Basaglar (biosimilar to Lantus)
• Tresiba surpasses TOUJEO in market share due to flexible dosing and lower hypoglycemia risk.
• Lantus retains a significant share due to established formulary presence.
• Biosimilars, such as Basaglar, have pressured pricing and market share from Lantus.

Regulatory and Market Approvals

• Approved in over 60 countries.
• FDA approval since 2015.
• Expanded indications in multiple jurisdictions over time.

Prescribing Trends

• Growing adoption driven by increased diabetes prevalence.
• Preference for long-acting insulins in type 1 and type 2 diabetes management.
• Shift toward biosimilars and cost-effective options affects market share.

Market Size and Growth Drivers

Global Diabetes Treatment Market

Year	Market Value (USD billions)	CAGR (2022-2027)	Drivers
2022	50	7.5%	Rising diabetes prevalence, innovation in insulin formulations
2027	75	8.5%	Aging population, increased diagnostics, insulin therapy adoption

Insulin Market Share for TOUJEO

• Estimated to hold approximately 15-20% market share among long-acting insulins globally.
• Revenue from insulin sales contributed significantly to Eli Lilly’s diabetes franchise.

Financial Trajectory and Revenue Outlook

Revenue Generation

• 2021: Insulin segment reported approximately USD 6.2 billion, with long-acting insulins comprising around USD 3.1 billion.
• 2022: Estimated growth of approximately 8-10%, reaching roughly USD 6.7 billion for insulin.
• 2023-2027 Forecast:

Year	Estimated Revenue (USD millions)	Key Factors
2023	800-850	Continued adoption, price optimization
2024	880-930	Expansion into emerging markets
2025	950-1,000	Increased market penetration
2026	1,050-1,100	Competitive pressures, biosimilar entry
2027	1,150-1,200	Patent expirations for competitors, formulary wins

Cost Dynamics

• Pricing Strategy: TOUJEO is positioned in the premium segment, with list prices higher than first-generation insulins.
• Reimbursement: Coverage is strong in the US and EU but varies across emerging markets.
• Manufacturing Costs: Remain steady due to process efficiencies and scale production.

Patent and Biosimilar Impact

• Patent for TOUJEO expired or set to expire by 2025.
• Biosimilar competition expected to emerge, exerting downward pressure on prices.
• Eli Lilly invests in lifecycle management and label expansion to mitigate patent loss.

Key Market Challenges and Opportunities

Challenges

• Entry of biosimilars diminishing pricing power.
• Pricing and reimbursement barriers in different regions.
• Competition from newer insulin analogs with improved profiles.
• Market saturation in mature regions like North America and Europe.

Opportunities

• Expand indication for type 2 and type 1 diabetes.
• Increase adoption in emerging markets with growing diabetes prevalence.
• Develop combination therapies and formulations.
• Leverage digital health integrations for better adherence and outcomes.

Policy and Regulatory Environment

• US FDA classifies insulin as a biologic, subject to biosimilar pathway.
• In the EU, biosimilar insulins can gain approval with comparability data.
• Price control measures increasingly influence revenue growth, especially in Europe.

Summary of Financial Risks and Strategic Responses

Risks

• Biosimilar price competition may reduce margins.
• Regulatory delays or hurdles for label expansions.
• Market saturation limits growth potential in mature markets.

Responses

• Product lifecycle management with new formulations or delivery systems.
• Expansion into early- and late-stage diabetes populations.
• Strengthening relationships with payors and healthcare providers.

Conclusion

TOUJEO remains a key product within Eli Lilly’s diabetes segment, with sustained growth driven by diabetes prevalence, formulation advantages, and global expansion. Its financial trajectory faces headwinds from biosimilar competition and pricing pressures but benefits from strategic innovation and market diversification.

Key Takeaways

• TOUJEO accounts for about 15-20% of long-acting insulin sales globally.
• Revenue is projected to grow at 8-10% annually through 2027, reaching over USD 1.2 billion.
• Patent expirations and biosimilar entrants by 2025 could pressure prices.
• Market expansion in emerging economies offers growth opportunities.
• Competitive differentiation hinges on formulation, delivery, and digital health integration.

FAQs

Q1: What are the primary competitors of TOUJEO?
Tresiba (Novo Nordisk), Lantus (Sanofi), and biosimilar insulins such as Basaglar.

Q2: How does biosimilar entry affect TOUJEO’s market share?
Biosimilars typically lead to price competition, reducing revenue per unit and potentially decreasing overall market share.

Q3: What is the expected impact of patent expiry on TOUJEO?
Patent expiry around 2025 may lead to increased biosimilar competition, putting downward pressure on prices and sales.

Q4: How does pricing strategy influence TOUJEO’s financial outlook?
Premium pricing sustains margins but may limit market penetration, especially where biosimilars are cheaper.

Q5: Which regions present the most growth opportunity for TOUJEO?
Emerging markets such as China, India, and Latin America, where diabetes prevalence is rising and access is expanding.

---

References

1. International Diabetes Federation. (2022). IDF Diabetes Atlas, 10th Edition.
2. Eli Lilly and Company. (2023). Annual Report.
3. MarketWatch. (2023). Insulin Market Overview.
4. U.S. Food and Drug Administration. (2015). FDA Approvals.
5. GlobalData. (2023). Biosimilar Insulin Market Analysis.